{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-115223","form_type":"8-K","ticker":"OCUL","cik":"0001393434","company_name":"OCULAR THERAPEUTIX, INC","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.845043+00:00","generated_at":"2026-06-08T14:18:58.697042+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ocular Therapeutix Q3: DEXTENZA revenue up 26% YoY to $15M; net loss narrows to $0.5M","bullets":["DEXTENZA net product revenue $15.0M (+26% vs Q3 2022), in line with Q2 2023; full-year guidance raised to upper end of $55-60M.","Net loss improved to $(0.5M) or $(0.01) per basic share vs $(24.2M) loss in Q3 2022; diluted EPS $(0.25).","FDA agreed under Special Protocol Assessment to pivotal SOL trial for AXPAXLI (wet AMD); first patient dosing expected by year-end.","Cash and cash equivalents $110.6M as of Sept 30, 2023; management believes sufficient to fund operations into 2025.","Top-line data from HELIOS trial (NPDR) expected Q2 2024; Phase 2 data for OTX-TIC (glaucoma) expected April 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-115223","json":"https://secwatch.observer/filing/0001104659-23-115223.json","markdown":"https://secwatch.observer/filing/0001104659-23-115223.md","text":"https://secwatch.observer/filing/0001104659-23-115223.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1393434/000110465923115223/0001104659-23-115223-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1393434/000110465923115223/tm2329748d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T14:18:58.697042+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"11c4632f34d686f610ff9fa4944aa24261fe560a","claim":"OCULAR THERAPEUTIX, INC reported third quarter ended September 30, 2023 results: revenue $15.0 million.","evidence_excerpt":"Treatment of Primary Open-Angle Glaucoma or Ocular Hypertension Anticipated to be Presented at ASCRS Meeting in Early April 2024 DEXTENZA ® Net Product Revenue in Q3 2023 was $15.0 million, Representing Growth of Approximately 26% Over Q3 2022 BEDFORD, Mass.–(BUSINESS WIRE)— November 7, 2023 – Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1393434/000110465923115223/0001104659-23-115223-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Revenue","value":"$15.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}